ClinicalTrials.gg
CompletedNCT07063823Updated Jul 28, 2026

A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease

A Phase 1 interventional study of HB-2121 in Celiac Disease and Healthy, sponsored by Nielsen Fernandez-Becker. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Nielsen Fernandez-Becker · Phase 1, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Celiac Disease with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Celiac Disease · United States.

Enrollment
53rd of 68
18 · median 46
Started
2025
with 4 others
Phase 1
16 of 103
1 open now
Registered
100th of 103
by date

Among the 103 studies in Celiac Disease with a site in United States, this one is the 53rd largest by enrollment of the 68 interventional ones that give a count, is one of 5 that started in 2025, is one of 16 in phase 1, and was the 100th registered.

Celiac Disease

353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.

Browse Celiac Disease studies →

Open to participants now

16 of the 103 studies in Celiac Disease with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Celiac Disease with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about the safety of a single dose of HB-2121 in adults. It will also look at how the body processes the drug. The main questions it aims to answer are:

  • What side effects do participants have after receiving HB-2121?
  • How much HB-2121 is in the blood over time?

Researchers will follow participants for 30 days after receiving HB-2121 to understand how the drug behaves in the body and how safe it is.

Participants will:

  • Receive one oral dose of HB-2121
  • Attend 4 in-person clinic visits for checkups, lab tests, and monitoring
  • Complete 2 remote visits that include safety lab assessments
  • Fill out a short daily questionnaire for 7 days about symptoms and health status
03

Conditions studied

  • Celiac Disease
  • Healthy

Browse trials for

Keywords

  • Celiac Disease
  • HB-2121
  • Healthy Volunteers
  • Gluten Intolerance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

General Inclusion Criteria (applies to all participants):

  • Aged 18 years and older
  • (BMI) between 18 and 45 kg/m2
  • Overall good health, as determined by medical history and a physical exam
  • No use of an drug in the past 12 weeks
  • Able and willing to follow study procedures and provide written
  • If of , participants must agree to use highly effective during the study period. The same applies to male participants with partners of childbearing potential

Additional Inclusion Criteria for Healthy Volunteers:

  • No diagnosis of celiac disease
  • No first-degree relatives (parent, sibling, child) with celiac disease
  • Able to eat gluten-containing foods without adverse effects
  • No history of gastrointestinal disorders such as Crohn's disease, ulcerative colitis, or eosinophilic enteritis

Additional Inclusion Criteria for Participants with Celiac Disease:

  • -confirmed diagnosis of celiac disease
  • No history of eosinophilic enteritis, autoimmune gastrointestinal disorders such as Crohn's disease or inflammatory bowel disease

Exclusion Criteria (applies to all participants):

  • Pregnant, breastfeeding, or planning to become pregnant during the study period
  • History of chemotherapy or pelvic radiation
  • History of congenital long syndrome or prolonged QTcF interval
  • Known infection, or positive test for or C, or other chronic liver disease
  • Current use of medications
  • Known allergy or sensitivity to any ingredients in the study drug
  • Active cancer or history of cancer
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    50 mg HB-2121 in Healthy Volunteers

    Participants in this arm will receive a one-time dose of 50 mg of HB-2121.

    Drug: HB-2121

  • Experimental
    150 mg HB-2121 in Healthy Volunteers

    Participants in this arm will receive a one-time dose of 150 mg of HB-2121.

    Drug: HB-2121

  • Experimental
    250 mg HB-2121 in Healthy Volunteers

    Participants in this arm will receive a one-time dose of 250 mg of HB-2121.

    Drug: HB-2121

  • Experimental
    50 mg HB-2121 in Participants with Celiac Disease

    Participants in this arm will receive a one-time dose of 50 mg of HB-2121.

    Drug: HB-2121

  • Experimental
    150 mg HB-2121 in Participants with Celiac Disease

    Participants in this arm will receive a one-time dose of 150 mg of HB-2121.

    Drug: HB-2121

  • Experimental
    250 mg HB-2121 in Participants with Celiac Disease

    Participants in this arm will receive a one-time dose of 250 mg of HB-2121.

    Drug: HB-2121

Interventions

  • DrugHB-2121

    HB-2121 taken once orally.

06

What researchers measure

Primary outcomes

  1. Frequency and severity of adverse events during the study window

    Adverse events (AEs) will be recorded and assessed for severity using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: From dosing through 30 days post-dose

Secondary outcomes

  1. Peak Plasma Concentration (Cmax) of HB-2121

    Blood samples will be collected at specified time points to determine the peak plasma concentration (Cmax) of HB-2121 following administration.

    Time frame: Pre-dose, and at 15, 30, 60, 120, 180, 240, and 360 minutes, and 1 day after dosing.

  2. Time to Peak Plasma Concentration (Tmax) of HB-2121

    Time to reach the maximum plasma concentration (Tmax) of HB-2121 will be determined from blood sample data collected at specified time points.

    Time frame: Pre-dose, and at 15, 30, 60, 120, 180, 240, and 360 minutes, and 1 day after dosing.

  3. Area Under the Plasma Concentration-Time Curve (AUC) for HB-2121

    The area under the plasma concentration versus time curve (AUC) for HB-2121 will be calculated using plasma concentration data from collected blood samples.

    Time frame: Pre-dose, and at 15, 30, 60, 120, 180, 240, and 360 minutes, and 1 day after dosing.

Other outcomes

  1. Frequency and identity of HB-2121 positive cells in the blood of healthy subjects and patients with celiac disease

    Blood samples will be collected after dosing, and peripheral blood mononuclear cells (PBMCs) will be analyzed using flow cytometry to determine the percentage of HB-2121+ cells among CD14+CD11c+ populations, with and without β7-integrin expression.

    Time frame: 60, 120, 180, 240, and 360 minutes, and 1 day after dosing

07

Study locations

1 site
  • Stanford University
    Stanford, California 94305, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Apr 2026, 7 months.

Of 14 phase 1 interventional studies under Celiac Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2025
First posted
Jul 14, 2025
StartActual
Aug 26, 2025
Primary completionActual
Apr 7, 2026
CompletionActual
Apr 7, 2026
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07063823
Lead sponsor
Nielsen Fernandez-Becker
Collaborators
Stanford's Innovative Medicines Accelerator, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Responsible party
Nielsen Fernandez-Becker (Clinical Professor, Medicine - Gastroenterology & Hepatology, Stanford University) — Sponsor-investigator
First posted
Jul 14, 2025
Start date
Aug 26, 2025
Primary completion
Apr 7, 2026
Completion
Apr 7, 2026
Last update
Jul 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion